Building upon clinical evidence demonstrating that SARS-CoV-2 virus directly activates the GSDMD pathway to trigger NET release and mediate organ damage in COVID-19 patients (25), where analysis of blood and lung tissue samples from hospitalized patients revealed GSDMD expression and NET formation associated with disease severity. This evidence concerns the gene GSDMD and COVID-19.